A Single Center, Prospective, Randomized Controlled, Phase II Clinical Study of Anti-PD-1 Antibody js001 (Treprizumab) Combined With TP Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Toripalimab (Primary) ; Cisplatin; Paclitaxel
Indications Carcinoma; Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

24 Oct 2023 Results (Up to Dec. 2022, n=99) assessing safety and efficacy of Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma presented at the 48th European Society for Medical Oncology Congress
02 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight